Sandra Philipp

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

Kim Papp, Andrew Blauvelt, Michael Bukhalo et al. · New England Journal of Medicine · 2017 · 504 citations · Full text

IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-γ are not

Kerstin Wolk, Harald S. Haugen, Wenfeng Xu et al. · Journal of Molecular Medicine · 2009 · 403 citations

Inflammation, Medicine, Immunodeficiencies +8

S3 – Guidelines on the treatment of psoriasis vulgaris (English version). Update

Alexander Nast, Wolf‐­Henning Boehncke, Ulrich Mrowietz et al. · JDDG Journal der Deutschen Dermatologischen Gesellschaft · 2012 · 271 citations

Increased Prevalence of Metabolic Syndrome in Patients with Acne Inversa

Robert Sabat, Akewit Chanwangpong, Sylke Schneider‐Burrus et al. · PLoS ONE · 2012 · 249 citations · Full text

Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study

Ian Landells, Colleen Marano, Ming-Chun Hsu et al. · Journal of the American Academy of Dermatology · 2015 · 220 citations · Full text